Drug Discovery
By
Can Merck’s $3 Billion Restructuring Drive Sustainable Growth Amidst Patent Challenges?
About MerckMerck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating…
Is Bristol Myers Squibb’s $300M Immunology Venture with Bain Capital Set to Pioneer Next-Gen Autoimmune Therapies?
Key Highlights About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology,…
How Is GSK’s Robust Q2 2025 Growth Powering Next-Gen Specialty Medicines and Vaccine Innovation?
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI for 100 Million Patients?
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
